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Pancreatic cancer reveals the worst prognosis among human cancers with little improvement in its clinical
outcome in the last three decades. We previously suggested that polypeptide N-acetylgalactosaminyltransferase 6
(GALNT6), which catalyzes O-type glycosylation of Mucin 1, might be a promising molecular target for drug
development for breast cancer. In this study, we report upregulation of GALNT6 in pancreatic cancer cells where
Mucin proteins are highly O-glycosylated. We found that knockdown of GALNT6 with small interfering RNA in
pancreatic cancer cells decreased the amount of Mucin 4 protein as well as that of its transcript, reduced the
levels of human epidermal growth factor receptor 2 and extracellular signal–regulated kinase, and significantly
reduced pancreatic cancer cell viability. Interestingly, knockdown of GALNT6 caused drastic morphological
changes of pancreatic cells, accompanied with the cadherin switching from P-cadherin to E-cadherin. Considering
important roles of Mucin 4 in growth and invasion, our findings imply that targeting GALNT6 is a very promising
therapeutic strategy for treatment of pancreatic cancer patients who still have very limited treatment modalities.
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Pancreatic cancer is the fourth leading cause of cancer-related death in
the United States and has kept the lowest 5-year survival rate among
common cancers due to the difficulty of diagnosis at an early stage, a
progressive phenotype, and limited options of treatment with
relatively low efficacy [1]. Current treatment options of pancreatic
cancer are based on either gemcitabine or a combination regimen
called FOLFIRINOX, which is composed of folinic acid (FOL),
5-fluorouracil (F), irinotecan (IRIN), and oxaliplatin (OX) [2].
However, because these treatment modalities are not highly effective,
more effective and less toxic treatment modalities should be
developed for pancreatic cancer patients.
Accumulating evidences have suggested that mucins are involved in
development, invasiveness, metastasis, and drug resistance of pancreatic
cancer [3]. Mucins, which are present as a membrane-bound form or as a
secreted form, enhance several oncogenic signal pathways and suppress cell
adhesion [4]. Particularly, in pancreatic cancer,Mucin 4protein expression
is known to be elevated and extensively modified with O-linked
oligosaccharides (O-glycosylation) [3]. Increase of O-glycosylatedMucin 4 was correlated with poor prognosis in patients with pancreatic
cancer [5,6].
The O-glycosylation is one of common posttranslational protein
modifications in cancer cells, and aberrant O-glycosylation is generally
considered to enhance functions of oncogenic proteins [7]. For example,
O-glycosylation is indicated to play important roles in protein processing,
stability, secretion, and thus activation of signaling pathways [8]. Such
abnormal O-glycosylation in cancer cells is attributed to upregulated
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family proteins that are involved in the initiation of the O-glycosylation
by transferring N-acetyl-alpha-D-galactosamine (GalNAc) to target
substrates [9]. We previously reported that GALNT6 was highly
transactivated and stabilizedMucin1 protein through theO-glycosylation
in breast cancer cells [10]. However, the underlying mechanism to cause
aberrant O-glycosylation of Mucins in pancreatic cancer has not been
fully investigated.
In the present study, we demonstrate that GALNT6 is overexpressed
in a subset of pancreatic cancer cell lines examined and plays imperative
roles in growth and invasion of pancreatic cancer cells. We also reveal
evidences supporting that GALNT6 is essential for O-glycosylation and
stabilization of Mucin 4 protein, and that knockdown of GALNT6
causes drastic morphological changes of pancreatic cells accompanied
with the cadherin switching from P-cadherin to E-cadherin. Our results
imply that GALNT6 is a promising molecular target for drug
development for pancreatic cancer.
Material and Methods
Cell Lines
Human pancreatic cancer cell lines ASPC-1, Capan-2, HPAF-II,
Panc02.03, Panc08.13, PANC-1, and PL45 were purchased from the
American Type Culture Collection (Rockville, MD). KP-1N,
MiaPaCa-2, and SUIT-2 cells were purchased from the Japanese
Collection of Research BioResources Cell Bank (Suita, Japan).
KLM-1, PK-45P, and PK-59 cells were provided by the Cell Resource
Center for Biomedical Research, Institute of Development, Aging
and Cancer, Tohoku University. KP4 cell was provided by RIKEN
BioResource Center (Tsukuba, Japan). The stocks of cell lines that
had been deposited in liquid nitrogen were used in this study. All cells
were cultured at 37°C in atmosphere of humidified air with 5% of
CO2 and in appropriate culture media (Life Technologies, Grand
Island, NY), such as RPMI1640 for ASPC-1, KLM-1, KP-1N,
Panc02.03, Panc08.13, PK-45P, and PK-59; DMEM for KP4,
PANC-1, and PL45; EMEM for HPAF-II, MiaPaCa-2, and SUIT-2;
and McCoy for Capan-2. Each medium was supplemented with 15%
(for Panc02.03 and Panc08.13) or 10% (for other cell lines) of fetal
bovine serum (Fisher Scientific, Pittsburgh, PA) and 1% of
antibiotic-antimycotic solution (Fisher Scientific).
Gene Silencing by RNA Interference
To knock down endogenous GALNT6 expression in pancreatic
cancer cells, we used small interfering RNAs (siRNAs) synthesized
from Sigma-Aldrich (St. Louis, MO). KLM-1 and Panc02.03 cells
were transfected with 200 pmol of oligo siRNA using Lipofectamine
RNAiMAX (Invitrogen, Carlsbad, CA) according to manufacturer’s
instructions. The target sequences of siRNA are 5′-GAGAAAUC-
CUUCGGUGACA-3′ for si-GALNT6 and 5′-GCACUGUUU-
CAAUGCCUUU-3′ for si-GALNT6-2, as previously described [10].
The siRNA Universal Negative Control (Sigma-Aldrich) was used for
si-control.
Cell Viability Assay
For methyl thiazolyl tetrazolium (MTT) assay, pancreatic cancer
cells were seeded into 24-well plates at 5 × 104 cells per well and
transfected with oligo siRNA. Then, cancer cells were cultured at
37°C under 5% CO2 for an additional 72 hours. The Cell Counting
Kit–8 (Dojindo Molecular Technologies, Inc., Kumamoto, Japan)was used for MTT reaction and examined the cell viability. After
reaction for 1 to 3 hours, 100 μl of supernatant was transferred into a
96-well plate and read in the iMark microplate absorbance reader
(Bio-Rad, Hercules, CA) at 450 nm of wavelength. All of these
experiments were done in triplicate.
Cell Invasion Assay
To examine cell invasiveness, 1 × 106 cells were seeded on
Transwell plates (Costar, Cambridge, MA) of 5-μm pore filters. After
adding 500 μl of 10% serum-containing medium to the lower
chamber of the well, pancreatic cancer cells were allowed to migrate
for 72 hours. The migrated cells on the lower side of the membrane
were photographed and counted with the ImageJ software [11].
Real-Time Reverse Transcription Polymerase Chain Reaction
(RT-PCR)
Total RNA was extracted from KLM-1 and Panc02.03 cells using
RNeasy Mini Kit (Qiagen, Valencia, CA), according to the
manufacturer’s instructions. Total RNA (1 μg) was reversely
transcribed using SuperScript III First-Strand Synthesis System
(Invitrogen) to generate cDNA. Aliquots of cDNA samples were
quantified by the real-time RT-PCR method. The RT-PCR was
performed using primers listed below using the ViiA 7 system (Life
Technologies). The expression level of GALNT6 or MUC4 was
normalized with that of GAPDH. The PCR primer sequences were
5′-GGATGAAACCTACCCCATCA-3′ and 5′-ACCGATGTGCT-
CAAAGTAGGA-3′ for GALNT6 , 5′-GAGGAATGAC-
CAGCTGCCTT-3′ and 5′-AGGGCCAGGGTGTCATAGAT-3′
for MUC4, and 5′-CGACCACTTTGTCAAGCTCA-3′ and
5′-GGTTGAGCACAGGGTACTTTATT-3′ for GAPDH.
Western Blot Analysis
To detect the expression of endogenous proteins in pancreatic
cancer cells, we performed Western blots with normalization of
protein amount by β-actin. Cells were lysed with the IP lysis buffer
(Thermo Scientific, Waltham, MA) containing protease inhibitor
cocktail III (Millipore, Billerica, MA). The proteins were separated by
electrophoresis using the any KD SDS-PAGE gel (Bio-Rad) and
transferred onto nitrocellulose membrane (GE Healthcare, Pitts-
burgh, PA). After blocking with the Block ACE solution (AbD
Serotec, Raleigh, NC), the membranes were incubated with the first
antibodies: anti-GALNT6 (Atlas Antibodies, Stockholm, Sweden),
anti–Mucin 4 (Santa Cruz Biothechnology, Santa Cruz, CA), anti–
E-cadherin (Abcam Biotech, Cambridge UK), anti–P-cadherin
(Abcam Biotech), anti–extracellular signal-regulated kinase (ERK)
(Abcam Biotech), anti–human epidermal growth factor receptor 2
(HER2) (Abcam Biotech), anti–β-actin (Sigma-Aldrich), anti–
Histone H3 (Abcam Biotech), or anti-Tubulin antibody (Millipore).
Finally, the membrane was incubated with horseradish peroxidase–
conjugated secondary antibodies (Santa Cruz Biothechnology), and
protein bands were visualized by the enhanced chemiluminescence
detection reagents (GE Healthcare). For the nuclear/cytoplasm
fractionation, KLM-1 and Panc02.03 cells were lysed using
NE-PER Nuclear and Cytoplasmic Extraction buffers (Thermo
Scientific) for 10 minutes on ice and then quick-spun for 15 seconds
to collect cytosolic lysate. Pellets were washed two times with
cytoplasmic lysis buffer and then lysed with the nuclear lysis buffer for
45 minutes on ice. The final lysates were spun for 20 minutes at
14,000 rpm at 4°C to collect nuclear lysates.
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Pancreatic cancer cells were seeded on Lab-Tek II chamber slide
system (Nalge Nunc International, Penfield, NY) before transfection
with oligo siRNAs. The cells were fixed with 4% paraformaldehyde in
PBS for 15 minutes and rendered permeable with 0.1% Triton X-100
in PBS at 4°C for 2.5 minutes. Subsequently, the cells were covered
with 3 % BSA in PBS at 4°C for 3 hours to block nonspecific
hybridization followed by incubation with antibodies of anti--
GALNT6 (1:100), anti–E-cadherin (1:100), or anti–β-catenin
(1:100). After washing with PBS for three times, cells were stained
by Alexa Fluor 488– or Alexa Fluor 594–conjugated secondary
antibodies (Molecular Probe, Eugene, OR) diluted at 1:1000. Finally,
nuclei were counterstained with 4′,6-diamidino-2-phenylindole, and
cells were examined by SP5 Tandem Scanner Confocal Microscope
(Leica Microsystems, Buffalo Grove, IL) at the University of Chicago
Microscopy Core Facility. Cytoskeleton structure was visualized by
staining with Alexa Fluor 488–conjugated phalloidin (Molecular
Probes).
In vitro O-Glycosylation
Recombinant GALNT6 protein was purchased from Abnova
(Walnut, CA), and MUC4 peptide (TSSASTGHATPLPVTD) was
synthesized from GenScript (Piscataway, NJ). Then 5 μM of the
MUC4 peptide was incubated with 0.5 μg of recombinant GALNT6
protein in 25 mM of Tris-HCl (pH 7.4), 10 mM ofMnCl2, and w/wo
50 μM of UDP-GalNAc at 37°C for 12 hours. The resultant peptides
were desalted by Zip-tip C18 (Merck Millipore, Billerica, MA),
mixed with 4 mg/ml α-cyano-4-hydroxycinnamic acid, andA
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Figure 1. Expression levels and knockdown effects of GALNT6 in pan
and Mucin 4 proteins in 14 pancreatic cancer cell lines were examined
MUC4 were successfully downregulated in KLM-1 and Panc02.03
si-control. (C) GALNT6 and Mucin 4 protein levels were reduced in KLM
compared with si-control. (D) The transcriptional level ofMUC4was do
Panc02.03 cells was assessed by MTT assays 7 days after transfec
significance with P value of b .001.analyzed with 4800 Plus MALDI-TOF (matrix-assisted laser
desorption ionization time-of-flight) mass spectrometer (Sciex,
Framingham, MA).
Statistical Analysis
Statistical significance was calculated by Student's t test using
Prism 6 software (GraphPad, San Diego, CA). A difference of P b .05
was considered to be significant.
Results
GALNT6 and Mucin 4 Expression in Pancreatic Cancer
We first examined expression levels of GALNT6 in pancreatic
cancers through publically available gene expression datasets. The
Oncomine database revealed that GALNT6 is highly expressed in
pancreatic cancer among 18 human cancer types listed (Supplemen-
tary Figure 1). Then, we confirmed by Western blot analyses high
levels of GALNT6 expression in 8 of 14 pancreatic cancer cell lines
(Figure 1A). We also examined expression levels of Mucin 4, a
dominantly expressed Mucin protein in pancreatic cancer [3], and
found that Mucin 4 protein levels are relatively higher in the
pancreatic cancer cell lines with higher GALNT6 expression
(Figure 1A).
Knockdown Effects of Endogenous GALNT6
To investigate the biological function of GALNT6 in pancreatic
cancer cells, we used siRNA to knock down GALNT6 expression
using two pancreatic cancer cell lines, KLM-1 and Panc02.03, in
which GALNT6 was highly expressed (Figure 1A). Knockdown ofPK
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creatic cancer cells. (A) Expression levels of endogenous GALNT6
by Western blot analysis. (B) The expression levels of GALNT6 and
cells 72 hours after transfection with si-GALNT6 compared with
-1 and Panc02.03 cells 72 hours after transfection with si-GALNT6
wnregulated by GALNT6 knockdown. (E) Cell viability of KLM-1 and
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these two pancreatic cancer cells compared with those transfected
with si-control (Figure 1B). Concordantly, Western blot analyses
showed significant reduction of GALNT6 protein in KLM-1 and
Panc02.03 cells (Figure 1C). Interestingly, we found that both
protein level and transcriptional expression level of Mucin 4 were
significantly decreased by GALNT6 knockdown (Figure 1, C and
D). Furthermore, knockdown of GALNT6 significantly reduced cell
viability (Figure 1E), which was verified by transfection of an
additional siRNA targeting GALNT6 (Supplementary Figure 2).
These results indicated that GALNT6 is likely to be essential for
proliferation and/or survival of pancreatic cancer cells.
O-Glycosylation of Mucin 4 by GALNT6
Mucin 4 protein contains tandemly repeated peptides that are
extensively O-glycosylated in pancreatic cancer cells [3]. Further-
more, previous reports showed that the GALNT family is directly
involved in the O-glycosylation of Mucin 4 [12]. To examine
whether GALNT6 can O-glycosylate Mucin 4, we performed in vitro
O-glycosylation assay using recombinant GALNT6 protein and a
Mucin 4 peptide (MUC4) corresponding to the core amino acids of
tandemly repeated sequences (TSSASTGHATPLPVTD). As a result
of MALDI-TOF mass spectrometry (MS) analysis, a molecule, which
was 203.07 Da larger (m/z = 1744.79) than unmodified MUC4BA
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Figure 2. O-glycosylation of Mucin 4 by GALNT6. (A) MALDI-TOF MS
without UDP-GalNAc. The upper right inserts show magnified spe
MALDI-TOF-TOF MS/MS spectra of unmodified MUC4 peptide (top)
[TSSASTGHAT]+ or [TSSASTGHAT][GalNAc]+ fragment ion, respectipeptide (m/z = 1541.72), was detected specifically in a UDP-GalNAc
(+) sample (Figure 2A), indicating O-glycosylation of the MUC4
peptide by GALNT6. Furthermore, subsequent MS/MS analysis
identified the shift of b10 fragment from m/z of 901.45
corresponding to an unmodified MUC4 peptide to b10’ position
with m/z of 1104.46 corresponding to an O-glycosylated MUC4
peptide (Figure 2B). This result illustrated that the 10th threonine
was predominantly O-glycosylated by GALNT6.
Suppression of Mucin 4 Signal Pathways by Knockdown of
GALNT6
Becuase Mucin 4 protein was significantly reduced by knockdown
of GALNT6, we further examined HER2 and ERK proteins, which
were reported to interact with Mucin 4 and play important roles in
pancreatic cancer cell proliferation and survival [13]. We observed
that GALNT6 knockdown significantly affected protein levels of
HER2 and ERK in KLM-1 pancreatic cancer cells (Figure 3A). We
also observed drastic morphological changes in KLM-1 cell by
GALNT6 knockdown compared with the cells transfected with
si-control as shown in Figure 3B. Hence, we examined protein levels
of the cadherin molecules and found that knockdown of GALNT6
caused the cadherin switching, decrease of P-cadherin, and increase of
E-cadherin (Figure 3A). These morphologic alterations were further
assessed by immunostaining with a fluorescence-labeled phalloidinMS2 (1541.7)
MS2 (1744.8)
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structure. The staining of F-actin was restricted to cellular membrane
in the si-control cells, but that of F-actin was markedly increased and
dispersed in the cytoplasm of the GALNT6-knockdown cells
(Figure 3C).
Cell Morphological Changes by GALNT6 Knockdown
We have demonstrated that knockdown of GALNT6 induced
drastic changes in the cytoskeleton structure. To identify the
mechanism underlying these alterations, we examined representative
cell adhesion molecules, an E-cadherin/β-catenin complex by
immunocytochemical staining. The knockdown of GALNT6
significantly increased staining of E-cadherin as well as β-catenin in
the cell-to-cell adhesion area in KLM-1 (Figure 4A) and in Panc02.03
cells (Figure 4B). These findings were in concordant with our
Western blot results from cellular fractions of cytoplasm and nucleus.
Knockdown of GALNT6 increased amount of β-catenin protein, and
most of the β-catenin protein was retained in the cytoplasm of
KLM-1 cells (Supplementary Figure S3).
Decreased Invasion and Survival of Pancreatic Cancer Cells by
GALNT6 Knockdown
Because upregulated Mucin 4 in pancreatic cancer cells was also
indicated to enhance the invasiveness [13], we further examined
knockdown effects of GALNT6 in the cell invasion using Transwellplates. Our results revealed that the invasive capacities of KLM-1 and
Panc02.03 cells were significantly decreased by GALNT6 knock-
down (Figure 5A). Because a critical role of Mucin 4 in resistance to
gemcitabine through activation of HER2 and ERK pathways was
indicated [14], we examined the effect of GALNT6 knockdown on
the gemcitabine sensitivity of pancreatic cancer cells. We first
measured the half-maximum inhibitory concentration (IC50) value
for gemcitabine to be 41.5 nM for KLM-1 cells and 28.4 nM for
Panc02.03 cells. Then, we treated the IC50 value of gemcitabine in
the KLM-1 and Panc02.03 cell lines transfected with si-control,
si-GALNT6, or si-MUC4. As expected, knockdown of either
GALNT6 or MUC4 sensitized these two pancreatic cancer cell
lines to gemcitabine (Figure 5, B and C). Because si-GALNT6
sensitized pancreatic cancer cells to gemcitabine more than si-MUC4,
GALNT6 might have additional O-glycan substrates involved in the
survival of pancreatic cancer cells.
Discussion
Despite all the efforts and attempts in the last few decades, the
outcomes of patients with pancreatic cancer have been improved
little. The overall 5-year survival rate for pancreatic cancer patients is
still less than 10%, and this disease is estimated to become the second
leading cause of cancer-related death in the United States by 2030
[15]. Although molecular targeted therapies have been widely
developed and applied for many types of cancer in the last two
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cancer [16]. In this study, we put our effort into identification of a
novel therapeutic target that can be applicable for drug development
of pancreatic cancer treatment.
Mucins are known to be highly expressed in pancreatic cancers and
play essential roles in activation of many oncogenic signals, resistance
to anticancer drugs, and blocking drug delivery to cancer cell. Among
them, Mucin 4 was reported to be significantly overexpressed and
extensively O-glycosylated in pancreatic tumor cells [6]. Mucin 4 can
associate with the HER2 receptor and affect tumorigenic processes
including proliferation, apoptosis, and epithelial-mesenchymal tran-
sition [17]. High expression of Mucin 4 also enhances a Src kinase
pathway leading to lysosomal degradation of E-cadherin. It was
reported that knockdown of Mucin 4 enhanced formation of an
E-cadherin/β-catenin complex and the membrane translocation of
β-catenin, resulting in the downregulation of the Wnt/β-catenin
signaling pathway in pancreatic cancer cells [18]. One of the possible
mechanisms leading to abundant Mucin 4 protein in pancreatic
cancer is the increase of protein stability caused by extensive
O-glycosylations in the backbone tandem-repeat region. Recent
studies suggested that O-glycosylation is one of the important
modifications in cancer cells conducted by GALNT family enzymes
that are involved in several cellular functions by catalyzing O-glycan
substrates. Indeed, we previously demonstrated that GALNT6 was
overexpressed in breast cancer cells and stabilized Mucin1 protein
through O-glycosylation [10].
In this study, we first analyzed GALNT6 and Mucin 4 expression
levels in pancreatic cancer cells and found that these proteins were
coexpressed in nearly half of the cell lines. Our knockdown
experiments suggested that GALNT6-induced O-glycosylation
might be critically important to stabilize Mucin 4 protein. We also
showed that MUC4 transcription level was decreased by knockdown
of GALNT6. Although the mechanism of this transcriptional
downregulation of Mucin 4 is unclear, we suspect some regulatorymechanism between Mucin 4 protein andMUC4 gene expression. In
fact, it was suggested that the cytosolic domain of Mucin 4 could be
translocated into the nucleus and interact with some transcription
factors leading to increased expression of the MUC4 gene [19]. In
addition, we assessed critical roles of GALNT6 in pancreatic cancer
cells in the Mucin 4 signaling pathways by investigating protein levels
of HER2 and ERK and found that protein levels of these two proteins
were abrogated by knockdown of GALNT6. More interestingly,
knockdown of GALNT6 resulted in drastic cell morphologic changes,
round shape, and enlarged cell size, like the mesenchymal to epithelial
transition, accompanied by the increase in the cell adhesion molecules
E-cadherin and β-catenin.
Both E-cadherin and P-cadherin interact with β-catenin and form
the cell adhesion complex linked to the actin cytoskeleton structure.
Normal epithelial tissues show high expression of E-cadherin, but
epithelial tumor cells often lose or reduce E-cadherin expression [20].
Transition of E-cadherin to P-cadherin, also called “cadherin
switching,” is often related with tissue disorder, cellular dedifferen-
tiation, and enhanced invasiveness of cancer cells [21]. Concordantly,
we previously reported that P-cadherin was significantly upregulated
in majority of human pancreatic cancers and its function was involved
in the increased motility of pancreatic cancer cells [22]. Our results
implied that knockdown of GALNT6 decreased P-cadherin
expression and accelerated the cell adhesion complex including
E-cadherin and β-catenin, resulting in reduction of the invasiveness of
pancreatic cancer cells.
Gemcitabine is currently used as one of the major chemothera-
peutic options to treat pancreatic cancer, but its clinical effect is very
limited because of rapid acquirement of drug resistance. Mucin 4 is
known to be involved in the chemoresistance and prolonged survival
of cancer cells, and knockdown of Mucin 4 was shown to sensitize
pancreatic cancer cells to gemcitabine through suppression of
mitogen-activated protein kinase, c-Jun N-terminal kinase, and
nuclear factor-κB pathways [23]. In concordance with these previous
272 Critical Role of GALNT6 in Pancreatic Cancer Tarhan et al. Neoplasia Vol. 18, No. 5, 2016findings, our GALNT6 knockdown experiments with gemcitabine
treatment revealed enhancement of pancreatic cancer cell death,
compared with gemcitabine alone, probably through the reduction of
Mucin 4 protein.
In summary, our results implicate that GALNT6 is essential in
O-glycosylation and stabilization of Mucin 4 protein. Because
O-glycosylation of Mucin 4 has critical roles in pancreatic
carcinogenesis, its modifying enzyme GALNT6 is an attractive
molecular target for the development of novel treatment for
pancreatic cancer.
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